CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 0.52×, lower than 95% of its Biotechnology peers (median 2.86×)
- FinancialsAltman Z-Score -1.08: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.29BHKD291.31M · vs all stocks (USD)
Revenue (TTM)
389.46MCNY49.64M · vs all stocks (USD)
Profit Margin
-84.55%vs Biotechnology peers
Beta
0.4500xvs all stocks
52-Week Change
-86.98%vs all stocks
Market Capitalization
2.29BHKD291.31M · vs all stocks (USD)
Enterprise Value
98.78MHKD12.59M · vs all stocks (USD)
Forward P/E
7.33xvs Biotechnology peers
Price to Sales (TTM)
1.31xvs Biotechnology peers
Price to Book (MRQ)
0.5244xvs Biotechnology peers
Enterprise to Revenue
0.2540xvs Biotechnology peers
Enterprise to EBITDA
-0.3900xvs Biotechnology peers
Profit Margin
-84.55%vs Biotechnology peers
Operating Margin
-235.26%vs Biotechnology peers
Return on Assets (TTM)
-14.05%vs Biotechnology peers
Return on Equity (TTM)
-38.30%vs Biotechnology peers
Revenue (TTM)
389.46MCNY49.64M · vs all stocks (USD)
Revenue per Share (TTM)
0.9420CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-5.40%vs Biotechnology peers
Gross Profit (TTM)
208.73MCNY26.61M · vs all stocks (USD)
EBITDA (TTM)
-253.45MCNY-32.31M · vs all stocks (USD)
Net Income (TTM)
-329.30MCNY-41.98M · vs all stocks (USD)
Operating Cash Flow (TTM)
-290.09MCNY-36.98M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-340.19MCNY-43.36M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
336.15MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
140.36MCNYFY2025 · Dec 31, 2025Gross Profit
195.79MCNYFY2025 · Dec 31, 2025Operating Income
-290.72MCNY-43.38M · vs all stocks (USD)
Pre-tax Income
-340.19MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-340.19MCNYFY2025 · Dec 31, 2025EBIT
-330.48MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-244.52MCNYFY2025 · Dec 31, 2025Research & Development
148.65MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
256.83MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.53MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.71MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.03CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.03CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
330.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
330.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-340.19MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-391.21MCNYFY2025 · Dec 31, 2025Free Cash Flow
-402.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
265.01MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-340.19MCNYFY2025 · Dec 31, 2025Stock-based Compensation
25.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
434.00KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-83.92MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-11.68MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.18MCNYFY2025 · Dec 31, 2025Purchase of Investments
-496.60MCNYFY2025 · Dec 31, 2025Sale of Investments
464.94MCNYFY2025 · Dec 31, 2025Other Investing Activity
19.52MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-23.83MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
268.52MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-280.65MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
0.00CNYFY2025 · Dec 31, 2025Net Financing Cash Flow
209.18MCNYFY2025 · Dec 31, 2025Shares Outstanding
363.37MSharesUpdated Sep 20, 2026Float Shares
99.67MSharesUpdated Sep 20, 2026% Held by Insiders
26.63%vs all stocks
% Held by Institutions
60.66%vs all stocks
Total Cash (MRQ)
732.97MCNY93.43M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.72CNYUpdated Sep 20, 2026Total Debt (MRQ)
321.12MCNY40.93M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3853xvs Biotechnology peers
Current Ratio (MRQ)
3.85xvs Biotechnology peers
Book Value per Share (MRQ)
2.29CNYUpdated Sep 20, 2026Total Assets
1.31BCNY194.92M · vs all stocks (USD)
Total Current Assets
1.04BCNYFY2025 · Dec 31, 2025Total Liabilities
421.00MCNYFY2025 · Dec 31, 2025Total Non-current Assets
263.63MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
151.28MCNYFY2025 · Dec 31, 2025Total Current Liabilities
269.71MCNYFY2025 · Dec 31, 2025Cash
265.01MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
265.01MCNYFY2025 · Dec 31, 2025Other Short-term Investments
523.24MCNYFY2025 · Dec 31, 2025Accounts Receivable
175.98MCNYFY2025 · Dec 31, 2025Inventory
35.46MCNYFY2025 · Dec 31, 2025Accounts Payable
15.36MCNYFY2025 · Dec 31, 2025Short-term Debt
182.20MCNYFY2025 · Dec 31, 2025Long-term Debt
135.19MCNYFY2025 · Dec 31, 2025Common Stock (Book)
51.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-3.72BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
885.28MCNY132.10M · vs all stocks (USD)
Treasury Stock
13.86MCNYFY2025 · Dec 31, 202552-Week Low
1.15HKDUpdated Sep 20, 202652-Week High
9.90HKDUpdated Sep 20, 202652-Week Change
-86.98%vs all stocks
Beta
0.4500xvs all stocks
50-Day MA
2.12HKDUpdated Sep 20, 2026200-Day MA
3.89HKDUpdated Sep 20, 2026Avg 10-Day Volume
158.58KSharesUpdated Sep 20, 2026Avg 30-Day Volume
134.07KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.9100CNYUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.52×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.52Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.85Altman Z-Score: -1.08
Financial Health
Altman Z-Score -1.08: distress zoneCritical
Altman Z-Score: -1.08
High structural barrier to entryNotable
Barrier to Entry: 100.455
Consistent revenue growth patternNotable
Growth Consistency Score: 1.43
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Aurisco Pharmaceutical Co., Ltd.
1 interpretationRevenue Growing With Receivables Growing
Quiñenco S.A.
1 interpretationRevenue Growing With Receivables Growing
Fleury S.A.
1 interpretationRevenue Growing With Receivables Growing